Ceribell reports 30% revenue growth and fully launches its delirium monitoring product
The point-of-care EEG company reported $29.3 million in third-quarter revenue and 747 active accounts, along with a new FDA 510(k) clearance for EEG trending and analysis software.
Ceribell said on November 3 that third-quarter revenue rose 30% to $29.3 million, with 747 active accounts after a company-record 35 net new customers. The maker of point-of-care EEG for hospitals also announced the full launch of its delirium monitoring product after a commercial pilot, and an FDA 510(k) clearance for quantitative EEG trending and amplitude-integrated EEG analysis. It forecasts 2026 revenue of $115 million to $117 million.
The net loss widened to $21.4 million from $13.5 million a year earlier. The figures are company-reported, and the guidance excludes any material contribution from its delirium, neonate and pediatric products, so the launch has not yet been factored into its forecast.
Learn more: Ceribell in the Directory · Ceribell’s stroke detection designation